280 related articles for article (PubMed ID: 12835546)
21. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
Kirsner RS; Heffernan MP; Antaya R
Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
[TBL] [Abstract][Full Text] [Related]
22. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
23. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.
Lakhanpaul M; Davies T; Allen BR; Schneider D
Exp Dermatol; 2006 Feb; 15(2):138-41. PubMed ID: 16433686
[TBL] [Abstract][Full Text] [Related]
24. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
25. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis.
Eichenfield LF; Ho V; Matsunaga J; Leclerc P; Paul C; Hanifin JM
J Dermatol; 2007 Apr; 34(4):231-6. PubMed ID: 17352719
[TBL] [Abstract][Full Text] [Related]
26. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.
Papp KA; Werfel T; Fölster-Holst R; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C
J Am Acad Dermatol; 2005 Feb; 52(2):240-6. PubMed ID: 15692468
[TBL] [Abstract][Full Text] [Related]
27. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
[TBL] [Abstract][Full Text] [Related]
28. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial.
Meurer M; Eichenfield LF; Ho V; Potter PC; Werfel T; Hultsch T
J Dermatolog Treat; 2010 May; 21(3):157-66. PubMed ID: 20394491
[TBL] [Abstract][Full Text] [Related]
29. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
30. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
31. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
Abramovits W; Fleischer AB; Jaracz E; Breneman D
J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
[TBL] [Abstract][Full Text] [Related]
32. Pimecrolimus: a review of its use in atopic dermatitis.
Wellington K; Noble S
Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
[TBL] [Abstract][Full Text] [Related]
33. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
37. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck.
Mensing CO; Mensing CH; Mensing H
Int J Dermatol; 2008 Sep; 47(9):960-4. PubMed ID: 18937664
[TBL] [Abstract][Full Text] [Related]
38. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.
Breuer K; Braeutigam M; Kapp A; Werfel T
Dermatology; 2004; 209(4):314-20. PubMed ID: 15539895
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study.
Yan AC; Honig PJ; Ming ME; Weber J; Shah KN
Arch Dermatol; 2010 Jan; 146(1):57-62. PubMed ID: 20083693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
